Rate My Professor A. Sanchez-Fueyo

Alberto Sánchez-Fueyo, MD PhD, is Professor of Hepatology at King's College London, serving as Academic Head and Director of the Institute of Liver Studies, as well as Honorary Transplant Hepatology Consultant at King’s College Hospital. His translational research centers on liver immunology, transplantation, and hepatobiliary neoplasms, with a focus on mechanisms of immunological tolerance, development of novel immunomodulatory therapies, regulatory T cell biology, cell therapy and engineering, and immunometabolism. He leads the Sánchez-Fueyo & Safinia Lab, which investigates biomarkers to stratify liver transplant recipients by immunological risk, the role of regulatory T cells in cancer and cardiovascular diseases, tumor microenvironment in hepatocellular carcinoma, phosphoproteomic biomarkers for patient stratification, and molecular features of cholangiocarcinoma and uncommon neoplasms such as those in Abernethy syndrome.

Professor Sánchez-Fueyo is a founder of Quell Therapeutics, a King's College London spin-off biotech established in 2019 to develop engineered regulatory T cell products for inflammatory disorders and transplant patients. He has held prior appointments at Hospital Clínic de Barcelona and Icahn School of Medicine at Mount Sinai, joining King's College London in 2012 as Head of the Liver Sciences Department. As principal investigator on the MRC-funded iMAPS project examining immunometabolic impacts of machine perfusion in liver transplantation, and co-investigator on grants including those for regulatory T cell optimization, extracorporeal photopheresis in transplantation, and somatic mutations in primary sclerosing cholangitis, he has received funding from MRC, NIHR, NIH, and EU. Notable publications include 'Cellular uptake and in vivo distribution of mesenchymal-stem-cell-derived extracellular vesicles are protein corona dependent' (Nature Nanotechnology, 2024; 130 citations), 'Randomized trial investigating the utility of a liver tissue transcriptional biomarker in identifying adult liver transplant recipients not requiring maintenance immunosuppression' (American Journal of Transplantation, 2025), and the highly cited 'Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs' (Gastroenterology, 2007). With over 12,000 citations across 200+ publications, his work significantly influences transplantation tolerance and liver disease therapies.